ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2219

Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort

Tobias Manigold1, Nicolas Bodmer2, Rosoux Elisabeth3, Deborah Markham4, Guillaume Fahrni3, Raphael Micheroli5, Lucas Bachmann2, Jonas Brändli6, Fabio Becce7 and Thomas Hügle8, 1Department of Rheumatology, Inselspital University Hospital Bern, Bern, Switzerland., Bern, Switzerland, 2Medignition, Zürich, Switzerland, 33) Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland, Lausanne, Switzerland, 4Department of Rheumatology, University Hospital Lausanne (CHUV), Switzerland, Lausanne, Switzerland, 5University Hospital Zurich, Zurich, Switzerland, 66) Data Science Team, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, Zürich, Switzerland, 7Lausanne University Hospital (CHUV), Lausanne, Switzerland, 8Lausanne University Hospital, Lausanne, Switzerland

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Crystal-induced arthritis, Diagnostic criteria, radiography, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) disease can mimic or interfere with the course of rheumatoid arthritis (RA). Previous studies suggest higher prevalence of Chondrocalcinosis (CC ), a precursor of CPPD, in seronegative RA patients. However, no significant treatment disparities were described in RA patients with or without coexisting CC.

Methods: We recently developed and validated a deep learning algorithm to classify the presence of chondrocalcinosis (CC) on hand radiographs, detecting the presence of CC at the TFCC, MCP-2, and MCP-3 sites with an accuracy of 0.86. In this study, we report the baseline characteristics of 1,344 RA patients of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry who underwent CC assessment using this algorithm and number of therapy lines and with adequate quality of the radiographs to run the algorithm.

A subgroup of patients was identified for whom the results of a clinical examination were available on the same date as the radiographs. In the event that radiographs of both hands were available, one was randomly selected. The following data were extracted: age, sex, seropositivity (RF, anti-CCP) status, number of therapy lines (four or more drugs vs. less), and DAS28 (CRP) ( > 5.1 vs. below). Two multivariable logistic regression analyses were conducted to assess the association of CC presence on DAS28 scores and the number of current RA medications, with adjustments made for patients’ age, sex, and serostatus.

Results: The mean age of the participants was 56.2 years (standard deviation (SD) 13.9), 954/1344 (71.0%) were female, and 916/1344 (68.2%) were seropositive. CC was present in 310 patients (23.1%) and overall not associated with the serostatus. Overall, 46 patients (3.4%) were taking at least four medications, and 82 (6.1%) exhibited high disease activity with DAS28-CRP >5.1. Overall, no association was found between CC presence and disease activity (OR 1.09 (95% CI: 0.62-1.90); p=0.771). In multivariable analyses, CC+ patients were more likely to take at least four drugs (odds ratio (OR): 2.54 (95% confidence interval (CI): 1.21-5.32); p=0.014) and were significantly older (CC-: 54.0 SD (13.5), CC+  63.0 SD (13.0), p< 0.001).

Conclusion: In this cross-sectional analysis of baseline characteristics of a large cohort of patients with RA who underwent CC assessment, we found a fairly strong association between the presence of CC and more therapy lines. Thus, overlap with CPPD may explain difficult-to-treat constellations in a subgroup of RA patients. Additional analyses will be performed in subgroups based on e.g. age, disease duration and type of treatment.


Disclosures: T. Manigold: None; N. Bodmer: None; R. Elisabeth: None; D. Markham: None; G. Fahrni: None; R. Micheroli: None; L. Bachmann: Medignition, 12, Shareholder; J. Brändli: None; F. Becce: Horizon Therapeutics, 2, Siemens Healthineers, 5; T. Hügle: AbbVie/Abbott, 6, ATREON SA, 4, GlaxoSmithKlein(GSK), 6, Novartis, 6, Roche, 6.

To cite this abstract in AMA style:

Manigold T, Bodmer N, Elisabeth R, Markham D, Fahrni G, Micheroli R, Bachmann L, Brändli J, Becce F, Hügle T. Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-of-chondrocalcinosis-with-disease-activity-and-drug-response-in-rheumatoid-arthritis-baseline-characteristics-of-the-swiss-rheumatoid-arthritis-outcomes-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-chondrocalcinosis-with-disease-activity-and-drug-response-in-rheumatoid-arthritis-baseline-characteristics-of-the-swiss-rheumatoid-arthritis-outcomes-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology